Clinical Algorithms for the Treatment of Patients With Chronic Myeloid Leukemia: The 2010 Perspective

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue , 2010, Pages S6-S13

  Jabbour, Elias ^a   Fullmer, Amber ^a   Cortés, Jorge E ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AP24534; BCR ABL; Bosutinib; Dasatinib; Imatinib; Nilotinib; Omacetaxine

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALGORITHM; ARTICLE; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MALE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; THIAZOLES;

MLCS; MLOWN;

EID: 77957357810     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.s.001     Document Type: Article

References (58)

1. Rowley, JD, Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973), 290–293.
2. Bartram, CR, de Klein, A, Hagemeijer, A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306 (1983), 277–280.
3. Sawyers, CL, Chronic myeloid leukemia. N Engl J Med 340 (1999), 1330–1340.
4. Sessions, J, Chronic myeloid leukemia in 2007. J Manag Care Pharm 13 (2007), 4–7.
5. Deininger, MW, Goldman, JM, Melo, JV, The molecular biology of chronic myeloid leukemia. Blood 96 (2000), 3343–3356.
6. Druker, BJ, Tamura, S, Buchdunger, E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996), 561–566.
7. Baccarani, M, Saglio, G, Goldman, J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006), 1809–1820.
8. Chronic myelogenous leukemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology–v.1.2009. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf Accessed: May 5, 2010.
9. Deininger, M, O'Brien, SG, Guilhot, F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 114, 2009, 462 (abstract 1126).
10. Hochhaus, A, Kreil, S, Corbin, AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002), 2190–2196.
11. Hochhaus, A, La Rosée, P, Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18 (2004), 1321–1331.
12. Apperley, JF, Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007), 1018–1029.
13. Kantarjian, HM, Larson, RA, Guilhot, F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115 (2009), 551–560.
14. Jabbour, E, Kantarjian, H, O'Brien, S, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113 (2009), 2154–2160.
15. Chronic myeloid leukemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology–v.1.2010. National Comprehensive Cancer Network [Web site]. Available at: www.NCCN.org/professionals/physician_gls/PDF/cml.pdf Accessed: June 1, 2009.
16. Baccarani, M, Cortes, J, Pane, F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27 (2009), 6041–6051.
17. Cortes, JE, Baccarani, M, Guilhot, F, et al. A phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 284 (2010), 424–430.
18. Baccarani, M, Rosti, G, Castagnetti, F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113 (2009), 4497–4504.
19. Baccarani, M, Druker, BJ, Cortes-Franco, J, et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood, 114, 2009, 142 (abstract 337).
20. Golemovic, M, Verstovsek, S, Giles, F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 (2005), 4941–4947.
21. Weisberg, E, Manley, PW, Breitenstein, W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005), 129–141.
22. Hantschel, O, Rix, U, Superti-Furga, G, Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49 (2008), 615–619.
23. Cortes, J, O'Brien, S, Jones, D, et al. Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia Chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood, 114, 2009, 144 (abstract 341).
24. Rosti, G, Castagnetti, F, Palandri, F, et al. Nilotinib 800 mg daily as frontline therapy of Ph+ chronic myeloid leukemia: dose delivered and safety profile for the GIMEMA CML working party. Blood, 114, 2009, 868 (abstract 2205).
25. Saglio S, Kim DW, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial. Paper presented at: the 51st Annual Meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA. Abstract LBA-1.
26. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009. Available at: http://packageinserts.bms.com/pi/pi_sprycel.pdf Accessed: May 5, 2010.
27. Cortes, J, Borthakur, G, O'Brien, S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood, 114, 2009, 143 (abstract 338).
28. Cortes, JE, Jones, D, O'Brien, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28 (2010), 398–404.
29. Cervantes, F, Baccarani, M, Lipton, J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study. Haematologica, 93, 2008, 372 (abstract 0934).
30. Rousselot, P, Corm, S, Paquette, R, et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib – A two-year update of the START-R study. Haematologica, 93, 2008, 48 (abstract 0122).
31. Kantarjian, H, Cortes, J, Kim, DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113 (2009), 6322–6329.
32. Kantarjian, H, Giles, F, Bhalla, K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood, 114, 2009, 464 (abstract 1129).
33. Hochhaus, A, Giles, F, Apperely, J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study. Haematologica, 94(suppl 2), 2009, 256 (abstract 0631).
34. Shah, NP, Kim, DW, Kantarjian HM, et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol, 25(18 suppl), 2007, 358s (abstract 7004).
35. Larson, RA, Ottmann, OG, Shah, NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035. Blood, 112, 2008, 1006 (abstract 2926).
36. Saglio, G, Kantarjian, HM, Hochhaus, A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Blood, 112, 2008, 1107 (abstract 3226).
37. Jabbour, E, Cortes, J, Kantarjian, H, Treatment selection after imatinib resistance in chronic myeloid leukemia. Targ Oncol 4 (2009), 3–10.
38. Tasigna [package insert], 2009, Novartis Pharmaceuticals Corporation, East Hanover, NJ Available at: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Accessed: May 5, 2010/.
39. Kantarjian, H, Giles, F, Wunderle, L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. N Engl J Med 354 (2006), 2542–2551.
40. O'Hare, T, Walters, DK, Stoffregen, EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005), 4500–4505.
41. Deininger, MW, Nilotinib. Clin Cancer Res 14 (2008), 4027–4031.
42. Cortes, J, Kantarjian, HM, Kim, D-W, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood, 112, 2008, 401 (abstract 1098).
43. Cortes, J, Talpaz, M, Deininger, M, et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. Blood, 114, 2009, 267 (abstract 643).
44. Cortes-Franco, J, Khoury, HJ, Nicolini, FE, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study. Blood, 114, 2009, 267 (abstract 644).
45. Cortes-Franco, J, Raghunadharao, D, Parikh, P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors: results of a multicenter phase 2/3 study. Blood, 114, 2009, 354 (abstract 861).
46. Shah, NP, Kim, D-W, Kantarjian, HM, et al. Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose. Blood, 112, 2008, 1107 (abstract 3225).
47. Kantarjian, HM, Kim, D-W, Dorlhiac-Llacer, P, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035. Blood, 112, 2008, 1106 (abstract 3224).
48. Cortes, J, Jabbour, E, Kantarjian, H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007), 4005–4011.
49. Jabbour, E, Kantarjian, H, Jones, D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008), 53–55.
50. Jabbour, E, Jones, D, Kantarjian, HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114 (2009), 2037–2043.
51. Soverini, S, Martinelli, G, Colarossi, S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome–positive leukemia. Blood 24 (2006), e51–e52.
52. Jabbour, E, Kantarjian, HM, Jones, D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112 (2008), 4839–4842.
53. Müller, MC, Cortes, JE, Kim, D-W, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood 114 (2009), 4944–4953.
54. Kantarjian, HM, Jabbour, E, Giles, FJ, et al. Prognostic factors for progression-free survival in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data. Blood, 114, 2009, 1278 (abstract 3298).
55. Jabbour, E, Kantarjian, H, O'Brien, S, et al. Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure. Blood, 114, 2009, 210 (abstract 509).
56. Quintas-Cardama, A, Kantarjian, H, O'Brien, S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25 (2007), 3908–3914.
57. Lipton, JH, Sriharsha, L, Bogomilsky, S, et al. Pleural effusions in patients treated with dasatinib: Results from two institutions, risk factors and management. J Clin Oncol, 25(18 suppl), 2007, 680s (abstract 17503).
58. Carpiuc, KT, Stephens, JM, Liou, SY, Botteman, MF, Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib. J Clin Oncol, 25(18 suppl), 2007, 680s (abstract 17501).